Guideline and Standard
China guideline for the screening and early detection of lung cancer(2021, Beijing)
He Jie, Li Ni, Chen Wanqing, Wu Ning, Shen Hongbing, Jiang Yu, Li Jiang, Wang Fei, Tian Jinhui, Consulting Group of China Guideline for the Screening and Early Diagnosis and Treatment of Lung Cancer, Expert Group of China Guideline for the Screening and Early Diagnosis and Treatment of Lung Cancer, Working Group of China Guideline for the Screening and Early Diagnosis and Treatment of Lung Cancer
Published 2021-03-23
Cite as Chin J Oncol, 2021, 43(3): 243-268. DOI: 10.3760/cma.j.cn112152-20210119-00060
Abstract
In China, the malignant tumor with the highest incidence and motality is lung cancer (LC). As screening and early detection and treatment are effective in reducing LC mortality, formulating a guideline in line with China′s national conditions for the screening and early detection and treatment of LC will greatly promote the homogeneity and accuracy of LC screening, and result in an improvement of the effectiveness of LC screening. Commissioned and directed by the Disease Prevention and Control Bureau of the National Health Commission of the People′s Republic of China, the guidline was initiated by the National Cancer Center of China and formulated with joint effort by experts from different disciplines. Following the principles and methods in WHO Handbook for Guideline Development, the guidline integrates the latest development in LC screening and early diagnosis and treatment worldwide while fully considering China′s national conditions and practical experience in LC screening. It provides detailed evidence-based recommendations for different aspects of LC screening, such as the targeted population, the technologies and the procedures, to regulate the practices of LC screening and early diagnosis and treatment and enhance the effectiveness of the prevention and control of LC in China.
Key words:
Lung neoplasms; Screening; Guideline
Contributor Information
He Jie
National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
Li Ni
National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
Chen Wanqing
National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
Wu Ning
National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
Shen Hongbing
Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing 211166, China
Jiang Yu
School of Public Health and Population Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China
Li Jiang
National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
Wang Fei
National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
Tian Jinhui
Evidence Based Medicine Center of Lanzhou University, Lanzhou 730000, China
Consulting Group of China Guideline for the Screening and Early Diagnosis and Treatment of Lung Cancer
Expert Group of China Guideline for the Screening and Early Diagnosis and Treatment of Lung Cancer
Working Group of China Guideline for the Screening and Early Diagnosis and Treatment of Lung Cancer
